InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,612.80
(
0.00%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.04
(
-1.00%
)
Bitcoin
62,068.58
(
-0.43%
)
Post# of 424038
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

IslandOfMisfitToys

Send PM Follow Ignore
Followers 72
Posts 6197
Boards Moderated 0
Alias Born 05/01/2011

IslandOfMisfitToys

Re: chas1232123 post# 218323

Wednesday, 10/09/2019 2:01:41 PM

Wednesday, October 09, 2019 2:01:41 PM

Post# of 424038
Incidentally, re "giant trial", this was actually a Feuerstein point awhile back re extracting maximum societal value from Vascepa.

You will note that AMRN has not added any significant trials going forward (yet). That seems bizarre to me if their intention is to GIA and expand the footprint of this miracle find as wide as possible.

Feuerstein said, "Thero should sell this company to a Big Pharma, and then they should run a zillion trials on it..." More or less.

And, all things considered, I think I agree with that. And a Big Pharma with very deep pockets and broad trial expertise is best placed to make that happen.

[Bracing myself now for the purist backlash...]

“The trick is in what one emphasizes. We either make ourselves miserable, or we make ourselves happy. The amount of work is the same.” Carlos Castaneda

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News
InvestorsHub NewsWire

FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Start posting your company's news
Only $200 per official company press release!